NCT01366209View on ClinicalTrials.gov

Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

PHASE3CompletedINTERVENTIONAL
Enrollment

555

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Pirfenidone

Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.

DRUG

Placebo

Placebo equivalent given as 3 divided doses 3 times per day.

Trial Locations (1)

94005

InterMune Inc., Brisbane

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT01366209 - Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter | Biotech Hunter